Trials of lipid lowering by various methods have clearly demonstrated the benefits, clinically
and angiographically. Evidence of slowed arterial disease progression and even regression …

The treatment of atherosclerosis using lipid-lowering drugs has evolved markedly over the
past decade. It has been driven by the results and implications of major clinical trials. There …

The consensus of evidence from angiographic trials demonstrates both coronary artery and
clinical benefits from lowering of lipids by a variety of regimens. The findings of reduced …

The small changes in luminal narrowing observed with lowering total cholesterol are
unlikely to be the principal mechanism by which lipid-lowering achieves a reduction in …

In the Familial Atherosclerosis Treatment Study (FATS), the reduction in clinical events
(75%) far outweighed the modest frequency and magnitude of lesion regression observed …

Lipid-lowering therapy leads to a great reduction of cardiovascular complications, but has
almost no effect on the degree of stenosis of coronary arteries. These and other studies have …

There is now substantial evidence from outcome trials, in individuals who have clinically
mani-fest coronary artery disease (CAD), confirming the benefits of treating plasma lipids as …

Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the
progression of atherosclerosis may be slowed or even reversed. The clinical benefit …

Purpose: To review the pathobiology and clinical implications of vulnerable coronary
atherosclerotic plaques and to discuss the identification of vulnerable plaques and …

The concept of plaque stabilization was developed to explain how lipid lowering could
decrease adverse coronary events without a substantial reduction in the regression of …